Defective ubiquitinylation of EGFR mutants of lung cancer confers prolonged signaling

K. Shtiegman; B. S. Kochupurakkal; Y. Zwang; G. Pines; A. Starr; A. Vexler; A. Citri; M. Katz; S. Lavi; Y. Ben-Basat; S. Benjamin; S. Corso; J. Gan; R. B. Yosef; S. Giordano; Y. Yarden

doi:10.1038/sj.onc.1210503

Defective ubiquitinylation of EGFR mutants of lung cancer confers prolonged signaling

K. Shtiegman
, B. S. Kochupurakkal
, Y. Zwang
, G. Pines
, A. Starr
, A. Vexler
, A. Citri
, M. Katz
, S. Lavi
, Y. Ben-Basat
, S. Benjamin
, S. Corso
, J. Gan
, R. B. Yosef
, S. Giordano
, Y. Yarden^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

133 Scopus citations

Abstract

Several distinct mutations within the kinase domain of the epidermal growth factor receptor (EGFR) are associated with non-small cell lung cancer, but mechanisms underlying their oncogenic potential are incompletely understood. Although normally ligand-induced kinase activation targets EGFR to Cbl-mediated receptor ubiquitinylation and subsequent degradation in lysosomes, we report that certain EGFR mutants escape this regulation. Defective endocytosis characterizes a deletion mutant of EGFR, as well as a point mutant (L858R-EGFR), whose association with c-Cbl and ubiquitinylation are impaired. Our data raise the possibility that refractoriness of L858R-EGFR to downregulation is due to enhanced heterodimerization with the oncogene product HER2, which leads to persistent stimulation.

Original language	English
Pages (from-to)	6968-6978
Number of pages	11
Journal	Oncogene
Volume	26
Issue number	49
DOIs	https://doi.org/10.1038/sj.onc.1210503
State	Published - 25 Oct 2007
Externally published	Yes

Bibliographical note

Funding Information:
We thank Drs Wallace Langdon and Dirk Bohmann for plasmids. Our laboratory is supported by research grants from the National Cancer Institute (grant CA72981, to YY), the Israel Cancer Research Fund and the German-Israel Foundation. YY is the incumbent of the Harold and Zelda Gold-enberg Professorial Chair.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Endocytosis
Gefitinib
Growth factor
NSCLC
Tyrosine kinase

Access to Document

10.1038/sj.onc.1210503

Cite this

@article{fab27adaf8de45c793282ebed32634a8,

title = "Defective ubiquitinylation of EGFR mutants of lung cancer confers prolonged signaling",

abstract = "Several distinct mutations within the kinase domain of the epidermal growth factor receptor (EGFR) are associated with non-small cell lung cancer, but mechanisms underlying their oncogenic potential are incompletely understood. Although normally ligand-induced kinase activation targets EGFR to Cbl-mediated receptor ubiquitinylation and subsequent degradation in lysosomes, we report that certain EGFR mutants escape this regulation. Defective endocytosis characterizes a deletion mutant of EGFR, as well as a point mutant (L858R-EGFR), whose association with c-Cbl and ubiquitinylation are impaired. Our data raise the possibility that refractoriness of L858R-EGFR to downregulation is due to enhanced heterodimerization with the oncogene product HER2, which leads to persistent stimulation.",

keywords = "Endocytosis, Gefitinib, Growth factor, NSCLC, Tyrosine kinase",

author = "K. Shtiegman and Kochupurakkal, \{B. S.\} and Y. Zwang and G. Pines and A. Starr and A. Vexler and A. Citri and M. Katz and S. Lavi and Y. Ben-Basat and S. Benjamin and S. Corso and J. Gan and Yosef, \{R. B.\} and S. Giordano and Y. Yarden",

note = "Funding Information: We thank Drs Wallace Langdon and Dirk Bohmann for plasmids. Our laboratory is supported by research grants from the National Cancer Institute (grant CA72981, to YY), the Israel Cancer Research Fund and the German-Israel Foundation. YY is the incumbent of the Harold and Zelda Gold-enberg Professorial Chair.",

year = "2007",

month = oct,

day = "25",

doi = "10.1038/sj.onc.1210503",

language = "אנגלית",

volume = "26",

pages = "6968--6978",

journal = "Oncogene",

issn = "0950-9232",

publisher = "Springer Nature",

number = "49",

}

TY - JOUR

T1 - Defective ubiquitinylation of EGFR mutants of lung cancer confers prolonged signaling

AU - Shtiegman, K.

AU - Kochupurakkal, B. S.

AU - Zwang, Y.

AU - Pines, G.

AU - Starr, A.

AU - Vexler, A.

AU - Citri, A.

AU - Katz, M.

AU - Lavi, S.

AU - Ben-Basat, Y.

AU - Benjamin, S.

AU - Corso, S.

AU - Gan, J.

AU - Yosef, R. B.

AU - Giordano, S.

AU - Yarden, Y.

N1 - Funding Information: We thank Drs Wallace Langdon and Dirk Bohmann for plasmids. Our laboratory is supported by research grants from the National Cancer Institute (grant CA72981, to YY), the Israel Cancer Research Fund and the German-Israel Foundation. YY is the incumbent of the Harold and Zelda Gold-enberg Professorial Chair.

PY - 2007/10/25

Y1 - 2007/10/25

N2 - Several distinct mutations within the kinase domain of the epidermal growth factor receptor (EGFR) are associated with non-small cell lung cancer, but mechanisms underlying their oncogenic potential are incompletely understood. Although normally ligand-induced kinase activation targets EGFR to Cbl-mediated receptor ubiquitinylation and subsequent degradation in lysosomes, we report that certain EGFR mutants escape this regulation. Defective endocytosis characterizes a deletion mutant of EGFR, as well as a point mutant (L858R-EGFR), whose association with c-Cbl and ubiquitinylation are impaired. Our data raise the possibility that refractoriness of L858R-EGFR to downregulation is due to enhanced heterodimerization with the oncogene product HER2, which leads to persistent stimulation.

AB - Several distinct mutations within the kinase domain of the epidermal growth factor receptor (EGFR) are associated with non-small cell lung cancer, but mechanisms underlying their oncogenic potential are incompletely understood. Although normally ligand-induced kinase activation targets EGFR to Cbl-mediated receptor ubiquitinylation and subsequent degradation in lysosomes, we report that certain EGFR mutants escape this regulation. Defective endocytosis characterizes a deletion mutant of EGFR, as well as a point mutant (L858R-EGFR), whose association with c-Cbl and ubiquitinylation are impaired. Our data raise the possibility that refractoriness of L858R-EGFR to downregulation is due to enhanced heterodimerization with the oncogene product HER2, which leads to persistent stimulation.

KW - Endocytosis

KW - Gefitinib

KW - Growth factor

KW - NSCLC

KW - Tyrosine kinase

UR - https://www.scopus.com/pages/publications/35549013373

U2 - 10.1038/sj.onc.1210503

DO - 10.1038/sj.onc.1210503

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 17486068

AN - SCOPUS:35549013373

SN - 0950-9232

VL - 26

SP - 6968

EP - 6978

JO - Oncogene

JF - Oncogene

IS - 49

ER -

Defective ubiquitinylation of EGFR mutants of lung cancer confers prolonged signaling

Abstract

Bibliographical note

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this